Value for money of medicine sampling and quality testing
Evidence from Indonesia
Bibliographic Data
| ID | 21879595 |
|---|---|
| Authors | Sara Valente de Almeida (0000-0001-9178-2105, Public Health England), Katharina Hauck (0000-0003-3138-4169, Imperial College London), Sarah Njenga (University of Oxford), Yunita Nugrahani (Pancasila University), Ayu Rahmawati (0009-0001-2757-6670, Pancasila University), Rahmi Mawaddati (Pancasila University), Stanley Saputra (0009-0006-5969-0183, Pancasila University), Amalia Hasnida (0000-0002-9264-334X, Erasmus University Rotterdam), Elizabeth Pisani (0000-0002-3674-631X, King's College London), Yusi Anggriani (0000-0001-7787-0539, Pancasila University), Adrian Gheorghe (0000-0002-0517-8807, Imperial College London) |
| Year | 2024 |
| Volume | 9 |
| Issue | 9 |
| Pages | e015402 |
| Publication date | 2024-09-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | BMJ Global Health (JOURNAL) |
| Journal identifiers | ISSN: 2059-7908 • E-ISSN: 2059-7908 |
| Publisher | BMJ (PUBLISHER • GB) |
| DOI | 10.1136/bmjgh-2024-015402 |
| PMID | 39313254 |
| OpenAlex | W4402750071 |
| Language | EN |
| Citations received | 1 |
| References cited | 14 |
BACKGROUND: Substandard and falsified medicines (SFMs) are a public health concern of global importance. Postmarket surveillance in the form of medicine sampling and quality testing can prevent and detect SFM, however, there is remarkably scarce evidence about the cost and value for money of these activities: how much do they cost and how effective are they in detecting SFM? METHODS: Between February and October 2022, Systematic Tracking of At Risk Medicines (STARmeds) collected and analysed for quality 1274 samples of 5 medicines from physical and online retail outlets in 7 Indonesian districts. We collated data on the resources consumed by STARmeds, related to all stages of medicines sampling and quality testing including design, fieldwork and laboratory analysis. We used activity-based costing principles to calculate the financial and economic cost of medicine quality surveillance from the perspective of a hypothetical medicines' regulator. We calculated the cost per day and per week of fieldwork, per sample collected and per substandard sample. We used bootstrapping to capture uncertainty in the number of samples collected, by seller location type (urban, rural and online). RESULTS: The total cost of sampling and testing medicines from the market was US$712 964 (current 2022 values). Laboratory costs represented the largest share (70%), followed by other direct costs (12%) and indirect costs (7%). On average, it costs STARmeds US$479 (95% CI US$462 to US$516) to collect one medicine sample and US$5990 (95% CI US$5601 to US$6258) to identify one substandard sample. CONCLUSION: Our findings bring urgently needed and novel information on the cost and value for money of medicine quality surveillance. These may support planning and budgeting of the Indonesian pharmaceutical regulator, but also of regulators and researchers elsewhere, particularly in low-income and middle-income settings, as well as international organisations with health regulation and quality of care remits
Economics · Public economics · Statistics · Value for money · Biosimilars and Bioanalytical Methods · Computer Science · Mathematics · Medicine · Pharmaceutical Economics and Policy · Pharmaceutical Quality and Counterfeiting · Philosophy
| Citations per year | 0.5 |
|---|---|
| Citation span | 2024 - 2024 (1) |
| Highly cited | No |